- Conditions
- Friedreich Ataxia
- Interventions
- Nomlabofusp, Placebo
- Drug
- Lead sponsor
- Larimar Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Chevy Chase, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 297
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Essential Tremor, Deep Brain Stimulation, Ataxia, Cerebellar Diseases
- Interventions
- No intervention
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Portland, Oregon
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- imetelstat sodium, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 18 more
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
- Interventions
- veliparib, temozolomide, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Spinocerebellar Ataxia Type I
- Interventions
- Lithium Carbonate
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- valproic acid
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 15
- States / cities
- Orange, California • Stanford, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- MOPP Regimen, Leucovorin Calcium, Mechlorethamine Hydrochloride, Methotrexate, Prednisone, Procarbazine Hydrochloride, Vincristine Sulfate, Conventional Surgery
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 3 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1989 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Palsy Supranuclear, Supranuclear Palsy, Progressive
- Interventions
- Repetitive transcranial magnetic stimulation (rTMS)
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Spinocerebellar Ataxia Type 3
- Interventions
- varenicline, placebo
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Gainesville, Florida • Tampa, Florida
- Conditions
- Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma
- Interventions
- Nivolumab, Relatlimab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Colorectal Neoplasms
- Interventions
- Nivolumab-relatlimab FDC, Regorafenib, TAS-102
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 769 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 20
- States / cities
- Springdale, Arkansas • Los Angeles, California • Norwich, Connecticut + 17 more
- Conditions
- Autism Spectrum Disorder
- Interventions
- tDCS
- Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2027
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Dyskinetic Cerebral Palsy, Dystonic Cerebral Palsy
- Interventions
- DBS
- Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 7 Years to 25 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Friedreich Ataxia
- Interventions
- Omaveloxolone, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 2 Years to 15 Years
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Gainesville, Florida • Tampa, Florida + 4 more
- Conditions
- Brain and Central Nervous System Tumors, Neurofibromatosis Type 1
- Interventions
- carboplatin, vinblastine sulfate
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 16 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- laromustine
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 10
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
- Conditions
- Celiac Disease, Cerebellar Ataxia, Healthy
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Spinocerebellar Ataxia Type 6
- Interventions
- Not listed
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Solid Tumors
- Interventions
- thioureidobutyronitrile
- Drug
- Lead sponsor
- Cellceutix Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ataxia Telangiectasia Louis-Bar, Ataxia Telangiectasia in Children, Ataxia Telangiectasia
- Interventions
- MBM-01
- Drug
- Lead sponsor
- Matrix Biomed, Inc.
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Friedreich Ataxia
- Interventions
- Elamipretide
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Leukoencephalopathies, LBSL, Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, White Matter Disease, Ataxia, Cerebellar, Genetic Disease
- Interventions
- Not listed
- Lead sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Other
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer, Head and Neck Cancer, DLBCL, Diffused Large B Cell Lymphoma, MSS, Microsatellite Stable Colon Cancer, TNBC, Triple Negative Breast Cancer, Melanoma, mCRPC, Metastatic Castration Resistant Prostate Cancer
- Interventions
- NIR178, PDR001
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 5
- States / cities
- Santa Monica, California • Tampa, Florida • Baltimore, Maryland + 2 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- systemic chemotherapy, laboratory biomarker analysis, therapeutic surgical procedure, radiation therapy
- Drug · Other · Procedure + 1 more
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 4 Years to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more